Medvolt was founded by Dr. Madhura Vipra and Mr. Ritvik Vipra. Dr. Madhura is a domain expert on molecular biology with over 30+ years of experience developing and commercializing drugs for global clients. On the other hand, Mr. Ritvik is a deep tech product development expert from IIT-Roorkee with over 6+ years of experience in the domain. Medvolt is a pioneering AI-enabled pharma R&D startup, specializing in preclinical drug discovery and knowledge discovery. Leveraging a proprietary generative AI and advanced physics-based in-silico platform, Medvolt significantly accelerates the drug discovery process. The company's technology reduces pre-clinical discovery time by 3x, costs by 15x and failure risks by 25%, enhancing R&D efficiency across various stages. Medvolt's AI-driven platform streamlines the identification, validation and optimization of novel compounds, integrating multi-omics data and advanced AI models to revolutionize pharmaceutical research. It features cutting-edge technologies for fixed-target and fixed-smile drug design and employs generative AI to facilitate rapid, cost-effective development of therapeutics. Moreover, Medvolt provides enriched research capabilities with high-throughput, gold-standard proprietary datasets and utilizes natural language processing to extract actionable insights from vast biomedical data. Their services extend from target identification to lead optimization, offering a comprehensive suite of tools to support drug repurposing and the creation of new chemical entities. Medvolt is dedicated to transforming the healthcare industry through innovative solutions, positioning itself at the forefront of biotech innovation.